



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

September 2015





HIV/AIDS Drug Treatment Program

Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.682.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

September 2015

N = 6932



Health Authority	Male	Female	All
FRASER	1298	387	1685
INTERIOR	353	93	446
NORTHERN	136	74	210
VANCOUVER COASTAL	3332	441	3773
VANCOUVER ISLAND	635	149	784
	5754	1144	6898
		Unknown/not stated:	34
		Total:	6932

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2010 - September 2015)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (September 2010 - September 2015)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (September 2010 - September 2015)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (September 2010 - September 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (September 2010 - September 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (September 2010 - September 2015)






1.8 Active and Inactive Participants (September 2010 - September 2015)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (September 2010 - September 2015)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (September 2010 - September 2015)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(September 2010 - September 2015)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (September 2010 - September 2015)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(September 2010 - September 2015)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (September 2010 - September 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(September 2010 - September 2015)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (September 2010 - September 2015)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT (September 2010 - September 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (September 2010 - September 2015)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(September 2010 - September 2015)**






1.20 Cumulative Resistance Testing Results by Resistance Category (September 2010 - September 2015)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (September 2010 - September 2015)





2.1 Duration of ARV treatment in the Province of BC, 1987-2015 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	650	5	<40	3
1988	23	8	0	8	8	500	8	<40	4
1989	22	56	2	58	53	510	55	<40	3
1990	21	63	1	64	59	540	62	<40	3
1991	21	39	3	42	38	564	42	<40	3
1992	21	67	6	73	57	570	72	<40	3
1993	20	151	15	166	147	560	161	<40	3
1994	19	98	12	110	88	545	105	<40	3
1995	19	128	26	154	122	530	144	<40	3
1996	17	373	62	435	370	595	420	<40	3
1997	15	313	41	354	308	595	337	<40	3
1998	14	219	48	267	221	550	253	<40	3
1999	14	185	42	227	186	560	214	<40	3
2000	14	143	38	181	154	585	172	<40	3
2001	14	135	34	169	142	566	165	<40	3
2002	13	141	34	175	145	540	168	<40	3
2003	12	176	36	212	182	590	202	<40	3
2004	11	179	44	223	192	565	214	<40	3
2005	10	213	53	266	224	585	252	<40	3
2006	9	216	48	264	218	530	250	<40	3
2007	8	276	53	329	272	580	314	<40	3
2008	7	318	73	391	316	620	372	<40	3
2009	6	349	77	426	370	620	407	<40	3
2010	5	322	76	398	336	635	382	<40	3
2011	4	370	75	445	379	650	417	<40	3
2012	3	318	68	386	323	640	369	<40	3
2013	2	304	75	379	306	600	363	<40	3
2014	1	320	59	379	318	620	370	<40	3
2015	0	291	45	336	303	530	331	<40	3
Total:		5776	1146	6922					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	782	2429	<40	2151	560
FEB-2014	6570	781	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1874	560
MAY-2014	6677	768	2120	<40	1887	560
JUN-2014	6644	783	1994	<40	1768	550
JUL-2014	6682	778	2179	<40	1930	550
AUG-2014	6703	774	2026	<40	1806	570
SEP-2014	6730	770	2284	<40	2005	550
OCT-2014	6760	761	2250	<40	1957	570
NOV-2014	6758	758	1920	<40	1706	580
DEC-2014	6770	765	1896	<40	1689	580
JAN-2015	6746	760	2429	<40	2111	580
FEB-2015	6796	753	1980	<40	1730	570
MAR-2015	6841	747	2173	<40	1892	570
APR-2015	6853	739	2148	<40	1901	580
MAY-2015	6892	739	2030	<40	1782	560
JUN-2015	6905	740	2256	<40	1931	580
JUL-2015	6930	739	2039	<40	1762	580
AUG-2015	6928	752	2076	<40	1714	580
SEP-2015	6932	747	2269	<40	1863	590

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1410	2265	100	6683	76	285
FEB-2014	1431	2152	73	496	67	490
MAR-2014	1433	2169	114	3726	99	340
APR-2014	1443	2144	112	128	90	400
MAY-2014	1414	2308	90	617	76	350
JUN-2014	1467	2052	96	423	82	380
JUL-2014	1459	2111	95	982	76	355
AUG-2014	1451	2161	87	208	72	365
SEP-2014	1451	2180	103	866	89	390
OCT-2014	1439	2250	84	257	62	395
NOV-2014	1452	2234	74	3945	64	400
DEC-2014	1473	2173	93	557	72	340
JAN-2015	1509	2069	105	1364	85	310
FEB-2015	1491	2138	99	75	85	380
MAR-2015	1465	2305	101	56	91	410
APR-2015	1471	2276	82	2279	66	475
MAY-2015	1454	2376	74	135	61	440
JUN-2015	1473	2305	94	106	88	430
JUL-2015	1467	2352	70	768	53	380
AUG-2015	1480	2304	82	3244	73	440
SEP-2015	1506	2231	88	116	72	370

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1410	2	30	144	136	35	11493
FEB-2014	6548	1431	9	40	139	159	9	11537
MAR-2014	6573	1433	9	36	151	146	25	11581
APR-2014	6587	1443	5	27	159	161	14	11617
MAY-2014	6646	1414	14	38	191	152	59	11667
JUN-2014	6618	1467	7	24	142	183	-28	11705
JUL-2014	6659	1459	8	34	176	159	41	11749
AUG-2014	6683	1451	6	18	165	149	24	11781
SEP-2014	6713	1451	2	25	168	159	30	11820
OCT-2014	6738	1439	7	21	159	146	25	11847
NOV-2014	6732	1452	12	19	135	144	-6	11871
DEC-2014	6745	1473	7	39	136	149	13	11920
JAN-2015	6713	1509	13	24	149	185	-32	11955
FEB-2015	6765	1491	7	36	188	162	52	12007
MAR-2015	6816	1465	7	29	173	142	51	12047
APR-2015	6815	1471	15	28	169	173	-1	12083
MAY-2015	6856	1454	9	33	170	148	41	12124
JUN-2015	6879	1473	5	36	154	162	23	12171
JUL-2015	6914	1467	5	25	165	148	35	12209
AUG-2015	6915	1480	5	20	145	158	1	12240
SEP-2015	6922	1506	2	34	157	180	7	12283

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	6557	0.72%	91.89%	6.31%	1.08%	100.00%
FEB-2014	50	6034	418	68	6570	0.76%	91.84%	6.36%	1.04%	100.00%
MAR-2014	50	6054	424	70	6598	0.76%	91.76%	6.43%	1.06%	100.00%
APR-2014	46	6067	422	76	6611	0.70%	91.77%	6.38%	1.15%	100.00%
MAY-2014	47	6138	418	74	6677	0.70%	91.93%	6.26%	1.11%	100.00%
JUN-2014	50	6107	416	71	6644	0.75%	91.92%	6.26%	1.07%	100.00%
JUL-2014	47	6147	415	73	6682	0.70%	91.99%	6.21%	1.09%	100.00%
AUG-2014	47	6170	414	72	6703	0.70%	92.05%	6.18%	1.07%	100.00%
SEP-2014	50	6185	424	71	6730	0.74%	91.90%	6.30%	1.05%	100.00%
OCT-2014	45	6208	434	73	6760	0.67%	91.83%	6.42%	1.08%	100.00%
NOV-2014	47	6217	424	70	6758	0.70%	91.99%	6.27%	1.04%	100.00%
DEC-2014	45	6230	421	74	6770	0.66%	92.02%	6.22%	1.09%	100.00%
JAN-2015	47	6185	440	74	6746	0.70%	91.68%	6.52%	1.10%	100.00%
FEB-2015	45	6227	451	73	6796	0.66%	91.63%	6.64%	1.07%	100.00%
MAR-2015	45	6293	436	67	6841	0.66%	91.99%	6.37%	0.98%	100.00%
APR-2015	44	6306	436	67	6853	0.64%	92.02%	6.36%	0.98%	100.00%
MAY-2015	47	6345	432	68	6892	0.68%	92.06%	6.27%	0.99%	100.00%
JUN-2015	49	6337	447	72	6905	0.71%	91.77%	6.47%	1.04%	100.00%
JUL-2015	46	6363	454	67	6930	0.66%	91.82%	6.55%	0.97%	100.00%
AUG-2015	47	6365	446	70	6928	0.68%	91.87%	6.44%	1.01%	100.00%
SEP-2015	44	6383	442	63	6932	0.63%	92.08%	6.38%	0.91%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3862 61%	36 86%	4269 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2430 38%	9 24%	2062 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3905 60%	17 63%	4286 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3896 59%	19 79%	4269 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3874 59%	37 76%	4246 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3850 59%	25 71%	4214 64%
FEB-2015	8 15%	2594 39%	8 15%	2229 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 85%	3886 59%	44 85%	4249 64%
MAR-2015	10 25%	2611 39%	10 25%	2254 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 75%	3919 59%	30 75%	4275 64%
APR-2015	10 29%	2627 40%	10 29%	2268 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	24 69%	3919 59%	24 69%	4275 64%
MAY-2015	8 20%	2640 40%	7 18%	2282 34%	0 0%	118 2%	0 0%	14 0%	0 0%	9 0%	32 80%	3933 59%	33 83%	4287 64%
JUN-2015	10 21%	2635 39%	10 21%	2289 34%	0 0%	115 2%	0 0%	15 0%	0 0%	9 0%	37 79%	3949 59%	37 79%	4300 64%
JUL-2015	4 11%	2659 40%	4 11%	2313 34%	0 0%	111 2%	0 0%	14 0%	0 0%	9 0%	34 89%	3950 59%	34 89%	4300 64%
AUG-2015	13 42%	2677 40%	12 39%	2336 35%	1 3%	111 2%	0 0%	12 0%	0 0%	9 0%	18 58%	3945 59%	18 58%	4285 64%
SEP-2015	17 40%	2721 40%	15 35%	2378 35%	0 0%	107 2%	1 2%	13 0%	0 0%	6 0%	26 60%	3916 58%	26 60%	4257 63%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2074 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2032 60%	18 69%	961 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2046 60%	8 47%	972 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	7 33%	2029 60%	14 67%	990 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%
MAY-2015	0 0%	12 0%	10 63%	2004 59%	6 38%	1020 30%	0 0%	360 11%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
JUN-2015	0 0%	11 0%	8 44%	1968 58%	10 56%	1037 31%	0 0%	359 11%	0 0%	5 0%	0 0%	1 0%	0 0%	18 1%
JUL-2015	0 0%	10 0%	1 7%	1960 58%	11 79%	1051 31%	1 7%	352 10%	0 0%	5 0%	0 0%	1 0%	1 7%	19 1%
AUG-2015	0 0%	11 0%	1 9%	1946 58%	7 64%	1057 31%	3 27%	346 10%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
SEP-2015	0 0%	11 0%	4 24%	1918 58%	12 71%	1066 32%	1 6%	339 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%
MAY-2015	0	0%	1	0%
JUN-2015	0	0%	1	0%
JUL-2015	0	0%	1	0%
AUG-2015	0	0%	1	0%
SEP-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1189 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1169 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%
APR-2015	4 67%	1148 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%
MAY-2015	7 58%	1139 44%	1 8%	309 12%	0 0%	887 34%	4 33%	260 10%
JUN-2015	2 29%	1133 44%	0 0%	317 12%	0 0%	877 34%	5 71%	262 10%
JUL-2015	8 89%	1122 44%	0 0%	311 12%	0 0%	880 34%	1 11%	260 10%
AUG-2015	4 80%	1104 43%	0 0%	307 12%	0 0%	879 35%	1 20%	253 10%
SEP-2015	8 89%	1096 43%	1 11%	305 12%	0 0%	873 35%	0 0%	256 10%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	76 5%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	74 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	74 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	14 58%	577 31%	8 33%	357 19%	0 0%	74 4%	2 8%	881 48%	0 0%	1 0%
MAR-2015	9 50%	600 32%	5 28%	368 20%	0 0%	69 4%	4 22%	870 47%	0 0%	2 0%
APR-2015	7 50%	629 33%	4 29%	374 20%	2 14%	67 4%	1 7%	863 45%	0 0%	2 0%
MAY-2015	11 65%	666 34%	4 24%	383 20%	1 6%	70 4%	2 12%	864 44%	0 0%	2 0%
JUN-2015	15 56%	712 35%	8 30%	397 20%	0 0%	72 4%	4 15%	875 43%	0 0%	1 0%
JUL-2015	11 58%	748 37%	4 21%	404 20%	0 0%	71 3%	4 21%	866 42%	0 0%	1 0%
AUG-2015	12 71%	786 38%	4 24%	413 20%	0 0%	70 3%	1 6%	855 41%	0 0%	1 0%
SEP-2015	17 81%	851 40%	2 10%	412 19%	0 0%	65 3%	2 10%	858 40%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2419	35.78	2190	32.40	1008	14.91	192	2.84	73	1.08	878	12.99
NOV-2014	2422	35.84	2159	31.95	1056	15.63	184	2.72	70	1.04	867	12.83
DEC-2014	2398	35.42	2144	31.67	1104	16.31	185	2.73	74	1.09	865	12.78
JAN-2015	2349	34.82	2125	31.50	1138	16.87	179	2.65	74	1.10	881	13.06
FEB-2015	2366	34.81	2112	31.08	1179	17.35	178	2.62	73	1.07	888	13.07
MAR-2015	2401	35.10	2113	30.89	1205	17.61	184	2.69	67	0.98	871	12.73
APR-2015	2394	34.93	2095	30.57	1241	18.11	184	2.68	67	0.98	872	12.72
MAY-2015	2400	34.82	2094	30.38	1278	18.54	178	2.58	68	0.99	874	12.68
JUN-2015	2369	34.31	2078	30.09	1325	19.19	170	2.46	72	1.04	891	12.90
JUL-2015	2374	34.26	2068	29.84	1353	19.52	170	2.45	67	0.97	898	12.96
AUG-2015	2368	34.18	2044	29.50	1385	19.99	167	2.41	70	1.01	894	12.90
SEP-2015	2331	33.63	2031	29.30	1450	20.92	168	2.42	63	0.91	889	12.82

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	36	3	3	9	3	16	469
MAR-2015	29	2	5	5	8	7	386
APR-2015	28	8	3	4	3	10	335
MAY-2015	33	4	6	9	5	8	290
JUN-2015	36	6	2	8	8	11	370
JUL-2015	25	6	2	2	6	7	380
AUG-2015	20	2	3	4	2	8	460
SEP-2015	34	8	1	5	3	15	451

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10027	2578
FEB-2014	10049	2571
MAR-2014	10062	2557
APR-2014	10092	2560
MAY-2014	10116	2554
JUN-2014	10151	2564
JUL-2014	10163	2552
AUG-2014	10212	2586
SEP-2014	10254	2596
OCT-2014	10276	2604
NOV-2014	10307	2626
DEC-2014	10348	2630
JAN-2015	10390	2660
FEB-2015	10436	2667
MAR-2015	10475	2676
APR-2015	10495	2688
MAY-2015	10549	2712
JUN-2015	10635	2759
JUL-2015	10704	2807
AUG-2015	10779	2868
SEP-2015	10878	2928

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
September 2015

N = 6932

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

September 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	10
	50+	18	28	12
	Total HSDA:	31	43	22
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	4	4	2
	35-49	19	25	13
	50+	45	60	35
	Total HSDA:	69	90	51
OKANAGAN	0-19	4	4	2
	20-34	21	22	17
	35-49	95	109	72
	50+	192	276	151
	Total HSDA:	312	411	242
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	17	17	14
	35-49	54	68	42
	50+	89	128	74
	Total HSDA:	166	219	131
Total HA:		578	763	446

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	4
	20-34	42	43	33
	35-49	181	217	137
	50+	344	492	272
Total HA:		578	763	446

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	450	606	353
Female	128	157	93

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	446	52	565	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	10
	5 years or more	7	5
	<5 years	8	7
	Total HSDA:	31	22
KOOTENAY BOUNDARY	10 years or more	32	21
	5 years or more	19	16
	<5 years	18	14
	Total HSDA:	69	51
OKANAGAN	10 years or more	167	120
	5 years or more	75	61
	<5 years	70	61
	Total HSDA:	312	242
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	84	58
	5 years or more	35	34
	<5 years	47	39
	Total HSDA:	166	131
Total HA:		578	446

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	299	209
	5 years or more	136	116
	<5 years	143	121
Total HA:		578	446

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	34	47	12	20
KOOTENAY BOUNDARY	59	108	24	40
OKANAGAN	190	644	71	228
THOMPSON/CARIBOO/SHUSWAP	122	406	42	102
Total:	405	1205	149	390

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	12
OKANAGAN	43
THOMPSON/CARIBOO/SHUSWAP	36
Total:	92

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	24	25	18
	35-49	120	131	90
	50+	165	225	134
	Total HSDA:	316	388	248
FRASER NORTH	0-19	20	20	4
	20-34	111	112	94
	35-49	356	407	257
	50+	442	690	367
	Total HSDA:	929	1229	722
FRASER SOUTH	0-19	11	11	5
	20-34	95	97	73
	35-49	363	412	296
	50+	405	600	341
	Unknown	0	1	0
	Total HSDA:	874	1121	715
Total HA:		2119	2738	1685

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	38	38	15
	20-34	230	234	185
	35-49	839	950	643
	50+	1012	1515	842
	Unknown	0	1	0
Total HA:		2119	2738	1685

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1597	2096	1298
Female	522	642	387

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1685	49	600	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	145	109
	5 years or more	89	67
	<5 years	82	72
	Total HSDA:	316	248
FRASER NORTH	10 years or more	440	322
	5 years or more	238	190
	<5 years	251	210
	Total HSDA:	929	722
FRASER SOUTH	10 years or more	389	308
	5 years or more	241	199
	<5 years	244	208
	Total HSDA:	874	715
Total HA:		2119	1685

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	974	739
	5 years or more	568	456
	<5 years	577	490
Total HA:		2119	1685

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	125	394	43	77
FRASER NORTH	224	1361	62	268
FRASER SOUTH	202	1155	52	348
Total:	551	2910	157	693

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	187
FRASER NORTH	613
FRASER SOUTH	485
Total:	1285

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	21	21	19
	35-49	84	98	67
	50+	193	312	166
	Total HSDA:	300	433	252
RICHMOND	0-19	7	7	1
	20-34	21	21	19
	35-49	44	47	37
	50+	74	113	61
	Total HSDA:	146	188	118
VANCOUVER	0-19	56	59	7
	20-34	411	419	311
	35-49	1621	1900	1222
	50+	2358	3896	1863
	Total HSDA:	4446	6274	3403
Total HA:		4892	6895	3773

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	65	68	8
	20-34	453	461	349
	35-49	1749	2045	1326
	50+	2625	4321	2090
Total HA:		4892	6895	3773

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4303	6063	3332
Female	587	830	441

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3773	51	590	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	165	130
	5 years or more	53	49
	<5 years	82	73
	Total HSDA:	300	252
RICHMOND	10 years or more	68	51
	5 years or more	33	25
	<5 years	45	42
	Total HSDA:	146	118
VANCOUVER	10 years or more	2210	1594
	5 years or more	1095	854
	<5 years	1141	955
	Never on ART	0	0
	Total HSDA:	4446	3403
Total HA:	4892	3773	

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	2443	1775
	5 years or more	1181	928
	<5 years	1268	1070
	Never on ART	0	0
Total HA:		4892	3773

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	359	53	89
RICHMOND	41	256	13	86
VANCOUVER	525	9692	204	5223
Total:	703	10307	270	5398

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	1
VANCOUVER	102
Total:	109

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	1
	20-34	24	26	19
	35-49	84	98	72
	50+	155	247	127
	Total HSDA:		265	373
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	13	14	7
	35-49	35	40	31
	50+	56	84	45
	Total HSDA:		106	140
SOUTH VANCOUVER ISLAND	0-19	8	8	1
	20-34	40	42	25
	35-49	213	252	164
	50+	374	583	291
	Total HSDA:		635	885
Total HA:		1006	1398	784

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	3
	20-34	77	82	51
	35-49	332	390	267
	50+	585	914	463
Total HA:		1006	1398	784

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	810	1129	635
Female	196	269	149

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	784	52	470	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	124	99
	5 years or more	67	57
	<5 years	74	63
	Total HSDA:	265	219
NORTH VANCOUVER ISLAND	10 years or more	47	36
	5 years or more	24	19
	<5 years	35	29
	Total HSDA:	106	84
SOUTH VANCOUVER ISLAND	10 years or more	313	215
	5 years or more	162	129
	<5 years	160	137
	Total HSDA:	635	481
Total HA:		1006	784

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	484	350
	5 years or more	253	205
	<5 years	269	229
Total HA:		1006	784

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	538	81	177
NORTH VANCOUVER ISLAND	113	231	47	73
SOUTH VANCOUVER ISLAND	181	1501	48	519
Total:	460	2270	176	769

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	46
NORTH VANCOUVER ISLAND	32
SOUTH VANCOUVER ISLAND	77
Total:	155

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	3
	35-49	17	19	12
	50+	17	22	9
	Total HSDA:	40	48	24
NORTH WEST	0-19	1	1	0
	20-34	8	12	6
	35-49	28	40	23
	50+	30	45	22
	Total HSDA:	67	98	51
NORTHERN INTERIOR	0-19	5	5	4
	20-34	28	31	19
	35-49	70	86	58
	50+	71	117	54
	Total HSDA:	174	239	135
Total HA:		281	385	210

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	7	7	4
	20-34	41	49	28
	35-49	115	145	93
	50+	118	184	85
Total HA:		281	385	210

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	176	245	136
Female	105	140	74

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	210	46	520	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	15	6
	5 years or more	11	8
	<5 years	14	10
	Total HSDA:	40	24
NORTH WEST	10 years or more	17	6
	5 years or more	24	22
	<5 years	26	23
	Total HSDA:	67	51
NORTHERN INTERIOR	10 years or more	51	33
	5 years or more	48	38
	<5 years	75	64
	Total HSDA:	174	135
Total HA:		281	210

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	83	45
	5 years or more	83	68
	<5 years	115	97
Total HA:		281	210

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	30	56	7	9
NORTH WEST	61	139	20	25
NORTHERN INTERIOR	97	379	24	183
Total:	188	574	51	217

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	20
Total:	45

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	7
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	19	34	18
	Total HA:	44	78	35
FRASER	FRASER EAST	31	39	24
	FRASER NORTH	66	95	49
	FRASER SOUTH	66	92	54
	Total HA:	163	226	127
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	22	41	18
	RICHMOND	8	13	7
	VANCOUVER	491	767	412
	Total HA:	521	821	437
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	72	36
	NORTH VANCOUVER ISLAND	13	22	10
	SOUTH VANCOUVER ISLAND	33	70	25
	Total HA:	93	164	71
NORTHERN	NORTH EAST	10	12	5
	NORTH WEST	33	56	29
	NORTHERN INTERIOR	61	92	55
	Total HA:	104	160	89
Total:		925	1449	759

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	589	936	478
Female	336	513	281

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	759	48	460	35

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Combination Therapy: using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.





Dolutegravir (DTG): an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

Efavirenz (Sustiva, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

Emtricitabine (FTC): a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

Famciclovir (Famvir): a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (MVC, Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.





Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).





PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a pill that contains DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

Tenofovir (Viread, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a pill that contains DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a pill that contains ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a pill that contains TENOFOVIR and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

